Background: Uveitis is a rare ocular adverse reaction of zoledronic acid, the specific clinical features are not clarified. This study was to investigate the clinical features of zoledronic acid-induced uveitis and provide reference for rational use of zoledronic acid.

Methods: We collected clinical data on zoledronic acid-induced uveitis for retrospective analysis by searching Chinese and English data up to October 31, 2024.

Results: Uveitis occurred in 44 patients with a median age of 66.5 years (range 47, 87) and 93.2% in females. The median time to onset of uveitis was 48 h (range 10, 192). Eye pain (86.4%), decreased vision (61.4%), and redness (50.0%) were the most commonly described symptoms. Uveitis could involve unilateral eyes (68.2%) and bilateral eyes (31.8%), and anterior uveitis was the main type (95.5%). Most patients had intraocular pressure within the normal range. Slit lamp examination mainly revealed cells (54.5%), flare (43.2%), and keratic precipitates (29.5%). After discontinuation of zoledronic acid (97.6%) and receipt of topical steroids (97.7%), systemic steroids (15.9%), and cycloplegics (72.7%), all patients showed improvement or recovery.

Conclusion: Zoledronic acid-induced uveitis mainly occurs within 72 h after the initial administration, and anterior uveitis is predominant. When zoledronic acid is used, patients should be informed of possible adverse eye reactions. Topical corticosteroids can be used as the main treatment for uveitis.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41433-024-03586-0DOI Listing

Publication Analysis

Top Keywords

zoledronic acid-induced
16
acid-induced uveitis
16
clinical features
12
zoledronic acid
12
uveitis
11
zoledronic
8
anterior uveitis
8
clinical
4
features treatment
4
treatment prognosis
4

Similar Publications

Background: Uveitis is a rare ocular adverse reaction of zoledronic acid, the specific clinical features are not clarified. This study was to investigate the clinical features of zoledronic acid-induced uveitis and provide reference for rational use of zoledronic acid.

Methods: We collected clinical data on zoledronic acid-induced uveitis for retrospective analysis by searching Chinese and English data up to October 31, 2024.

View Article and Find Full Text PDF

Zoledronic acid, or zoledronate, is a nitrogen-containing bisphosphonate widely used to treat osteoporosis and metastatic bone disease. It inhibits osteoclast function by binding to hydroxyapatite, reducing bone resorption and increasing bone mineral density. Despite its proven efficacy in increasing bone mineral density and reducing the incidence of fractures, adverse effects have been documented, including ocular side effects such as acute anterior uveitis.

View Article and Find Full Text PDF

The most frequently reported adverse reaction to zoledronic acid is an acute phase reaction resembling influenza. While rarer adverse events such as osteonecrosis of the jaw and atypical femoral fractures have gained significant recognition, the ocular adverse effects, particularly scleritis, are not yet fully comprehended. Here, we present the case of a 75-year-old female patient with osteoporosis who developed bilateral redness and intense eye pain 48 h after receiving a 5 mg intravenous dose of zoledronic acid.

View Article and Find Full Text PDF

Orthodontic tooth movement (OTM) is thought to be impeded by bisphosphonate (BP) therapy, mainly due to increased osteoclast apoptosis and changes in the periodontal ligament (PdL), a connecting tissue between the alveolar bone and teeth. PdL cells, mainly fibroblasts (PdLFs), are crucial regulators in OTM by modulating force-induced local inflammatory processes. Recently, we identified the TGF-β/BMP superfamily member GDF15 as an important modulator in OTM, promoting the pro-inflammatory mechanoresponses of PdLFs.

View Article and Find Full Text PDF

Zoledronic acid-induced severe lymphopenia.

Osteoporos Int

September 2023

Physical Medicine and Rehabilitation Clinic, Konya Beyhekim Training and Research Hospital, Devlethane Street No:2/A, 42060, Selçuklu/Konya, Turkey.

Although anemia, thrombocytopenia, and mild lymphopenia have been reported in the acute phase response after zoledronic acid, severe lymphopenia has not been reported. This article describes a case of severe lymphopenia following a 5 mg zoledronic acid infusion administered to treat osteoporosis. Zoledronic acid is used to treat osteoporosis, hypercalcemia, Paget's disease, and solid malignancies, including multiple myeloma, breast cancer, and prostate cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!